Ionis Pharmaceuticals, Inc. Deferred Income Tax Expense (Benefit)
Ionis Pharmaceuticals, Inc. (IONS) reported Deferred Income Tax Expense (Benefit) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-02-26
- Ionis Pharmaceuticals, Inc. deferred income tax expense (benefit) for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- Ionis Pharmaceuticals, Inc. deferred income tax expense (benefit) for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- Ionis Pharmaceuticals, Inc. deferred income tax expense (benefit) for the quarter ending 2021-06-30 was $0.00, a 100.00% decline year-over-year.
- Ionis Pharmaceuticals, Inc. deferred income tax expense (benefit) for the quarter ending 2021-03-31 was $0.00.
- Ionis Pharmaceuticals, Inc. deferred income tax expense (benefit) for fiscal 2025 was $0.00.
- Ionis Pharmaceuticals, Inc. deferred income tax expense (benefit) for fiscal 2024 was $0.00.
- Ionis Pharmaceuticals, Inc. deferred income tax expense (benefit) for fiscal 2023 was $0.00.
- Ionis Pharmaceuticals, Inc. deferred income tax expense (benefit) for fiscal 2022 was $0.00.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 3 month as first filed | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 6 month as first filed | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 9 month as first filed | Deferred Income Tax Expense (Benefit) 12 month | Deferred Income Tax Expense (Benefit) 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-26 | |||||||
| 2024-12-31 | $0.00 10-K · filed 2026-02-26 | |||||||
| 2023-12-31 | $0.00 10-K · filed 2026-02-26 | |||||||
| 2022-12-31 | $0.00 10-K · filed 2025-02-19 | |||||||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-21 | $0.00 derived: sum of 2 quarters · filed 2024-02-21 | $0.00 derived: sum of 3 quarters · filed 2024-02-21 | $0.00 10-K · filed 2024-02-21 | ||||
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $0.00 derived: sum of 2 quarters · filed 2021-11-03 | $0.00 10-Q · filed 2021-11-03 | $340.08M derived: sum of 4 quarters · filed 2023-02-22 | ||||
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $0.00 10-Q · filed 2021-08-04 | $340.08M derived: sum of 3 quarters · filed 2023-02-22 | $341.53M derived: sum of 4 quarters · filed 2023-02-22 | ||||
| 2021-03-31 | $0.00 10-Q · filed 2021-05-05 | $340.08M derived: sum of 2 quarters · filed 2023-02-22 | $341.53M derived: sum of 3 quarters · filed 2023-02-22 | $344.02M derived: sum of 4 quarters · filed 2023-02-22 | ||||
| 2020-12-31 | $340.08M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $341.53M derived: sum of 2 quarters · filed 2023-02-22 | $344.02M derived: sum of 3 quarters · filed 2023-02-22 | $341.73M 10-K · filed 2023-02-22 | $313.27M 10-K · filed 2021-02-24 | |||
| 2020-09-30 | $1.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $3.94M derived: sum of 2 quarters · filed 2021-11-03 | $1.65M 10-Q · filed 2021-11-03 | -$3.48M 10-Q · filed 2020-11-04 | -$1.55M derived: sum of 4 quarters · filed 2022-02-25 | |||
| 2020-06-30 | $2.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $196.00K 10-Q · filed 2021-08-04 | -$2.51M 10-Q · filed 2020-08-05 | -$3.00M derived: sum of 3 quarters · filed 2022-02-25 | -$13.34M derived: sum of 4 quarters · filed 2022-02-25 | |||
| 2020-03-31 | -$2.29M 10-Q · filed 2021-05-05 | -$3.44M 10-Q · filed 2020-05-06 | -$5.49M derived: sum of 2 quarters · filed 2022-02-25 | -$15.82M derived: sum of 3 quarters · filed 2022-02-25 | -$14.93M derived: sum of 4 quarters · filed 2022-02-25 | |||
| 2019-12-31 | -$3.20M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | -$13.53M derived: sum of 2 quarters · filed 2022-02-25 | -$12.64M derived: sum of 3 quarters · filed 2022-02-25 | $904.00K 10-K · filed 2022-02-25 | -$7.10M 10-K · filed 2020-03-02 | |||
| 2019-09-30 | -$10.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | -$9.45M derived: sum of 2 quarters · filed 2020-11-04 | $4.10M 10-Q · filed 2020-11-04 | -$286.41M derived: sum of 4 quarters · filed 2021-02-24 | ||||
| 2019-06-30 | $887.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $14.44M 10-Q · filed 2020-08-05 | -$276.07M derived: sum of 3 quarters · filed 2021-02-24 | -$276.07M derived: sum of 4 quarters · filed 2021-02-24 | ||||
| 2019-03-31 | $13.55M 10-Q · filed 2020-05-06 | -$276.96M derived: sum of 2 quarters · filed 2021-02-24 | -$276.96M derived: sum of 3 quarters · filed 2021-02-24 | -$276.96M derived: sum of 4 quarters · filed 2021-02-24 | ||||
| 2018-12-31 | -$290.51M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | -$290.51M derived: sum of 2 quarters · filed 2021-02-24 | -$290.51M derived: sum of 3 quarters · filed 2021-02-24 | -$290.51M 10-K · filed 2021-02-24 | ||||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $0.00 derived: sum of 2 quarters · filed 2019-11-06 | $0.00 10-Q · filed 2019-11-06 | |||||
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | $0.00 10-Q · filed 2019-08-08 | ||||||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-09 | |||||||
| 2017-12-31 | $0.00 10-K · filed 2020-03-02 | |||||||
| 2016-12-31 | $0.00 10-K · filed 2019-03-01 | |||||||
| 2015-12-31 | $0.00 10-K · filed 2018-02-28 | |||||||
| 2014-12-31 | -$11.38M 10-K · filed 2017-03-01 | |||||||
| 2013-12-31 | -$5.92M 10-K · filed 2016-02-26 | |||||||
| 2012-12-31 | -$9.11M 10-K · filed 2015-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |